ClinicalTrials.gg
Not yet recruitingNCT07543848Updated Apr 22, 2026

A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer

A Phase 2 interventional study of Serplulimab and Oncolytic Virus H101 in Rectal Neoplasms and Rectal Adenocarcinoma, sponsored by Chongqing University Cancer Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Chongqing University Cancer Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Rectal Neoplasms with a site in China — 228 open to participants now, 267 under way, 42 of them phase 3. Rectal Neoplasms · China.

Planned enrollment
349th of 373
20 · median 100
Started
2026
with 50 others
Phase 2
155 of 463
95 open now
Primary completion
2028-12
later than 227 of 266 live
Registered
428th of 463
by date

Among the 463 studies in Rectal Neoplasms with a site in China, this one is the 349th largest by planned enrollment of the 373 interventional ones that give a count, is one of 51 that started in 2026, is one of 155 in phase 2, reaches primary completion later than 227 of the 266 other live ones, and was the 428th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

228 of the 463 studies in Rectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

223 more — sign in →

All 228 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Rectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the safety and effectiveness of a combination treatment including a PD-1 inhibitor (serplulimab), oncolytic virus H101, short-course radiotherapy, and XELOX chemotherapy as total neoadjuvant therapy in patients with locally advanced low rectal cancer (cT1-3N0M0).

In this prospective, multicenter, single-arm phase II study, eligible patients will receive a standardized treatment regimen consisting of intratumoral injection of oncolytic virus H101, short-course radiotherapy, chemotherapy, and immunotherapy over multiple cycles. Tumor response will be assessed using imaging, endoscopy, and clinical evaluation after completion of treatment.

The primary objective is to determine the 1-year clinical complete response rate. Secondary outcomes include tumor response rate, organ preservation rate, survival outcomes, and treatment safety.

The results of this study may help improve treatment strategies for rectal cancer, increase the rate of complete response, and provide more opportunities for organ preservation while maintaining safety.

Read the detailed description

Rectal cancer is a common malignancy with a significant impact on patient survival and quality of life. For patients with locally advanced rectal cancer, the current standard treatment typically includes neoadjuvant chemoradiotherapy followed by surgery. Although this approach can achieve tumor control, the rate of complete response remains limited, and surgery may result in permanent stoma or impaired bowel, urinary, and sexual function. Therefore, there is a need to develop more effective treatment strategies that can improve tumor response and increase the chance of organ preservation.

Most rectal cancers are mismatch repair-proficient or microsatellite stable (pMMR/MSS), which generally show limited response to immunotherapy alone. Recent studies suggest that combination strategies may enhance treatment efficacy by modifying the tumor microenvironment and improving immune response.

This study is designed to evaluate a novel combination treatment approach that includes a PD-1 inhibitor (serplulimab), an oncolytic virus (H101), short-course radiotherapy, and XELOX chemotherapy as total neoadjuvant therapy. The oncolytic virus H101 selectively infects and destroys tumor cells while stimulating anti-tumor immune responses. Radiotherapy may further enhance immune activation by promoting tumor antigen release, and chemotherapy can improve tumor sensitivity to treatment. The combination of these therapies is expected to have a synergistic effect. :contentReference[oaicite:0]{index=0}

This is a prospective, multicenter, single-arm phase II clinical trial. Approximately 20 patients with low rectal adenocarcinoma (cT1-3N0M0) will be enrolled. All participants will receive a standardized treatment regimen consisting of intratumoral injections of H101, short-course radiotherapy, and systemic treatment with serplulimab and XELOX chemotherapy over multiple cycles. :contentReference[oaicite:1]{index=1}

Tumor response will be evaluated after completion of the total neoadjuvant therapy using imaging, endoscopy, and clinical assessments. Patients who achieve clinical complete response may enter a non-surgical management strategy with close follow-up, while others may proceed to surgery based on clinical evaluation.

The primary endpoint of this study is the 1-year clinical complete response rate. Secondary endpoints include objective response rate, organ preservation rate, tumor downstaging, recurrence-free survival, disease-free survival, overall survival, and safety outcomes. :contentReference[oaicite:2]{index=2}

The findings of this study may provide evidence for a new treatment strategy for rectal cancer that improves tumor response and increases the possibility of organ preservation while maintaining acceptable safety.

03

Conditions studied

  • Rectal Neoplasms
  • Rectal Adenocarcinoma

Browse trials for

Keywords

  • Rectal Cancer
  • Total Neoadjuvant Therapy
  • Combination Therapy
  • Serplulimab
  • PD-1 Inhibitor
  • Oncolytic Virus H101
  • XELOX Chemotherapy
  • Short-course Radiotherapy
  • Organ Preservation
  • Clinical Complete Response
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Participants must meet all of the following criteria:

  1. Age 18 to 80 years, male or female.
  2. confirmed low rectal adenocarcinoma, with tumor located ≤5 cm from the anal verge.
  3. Clinical stage T1-3N0M0 according to AJCC staging criteria.
  4. Mismatch repair-proficient (pMMR) or microsatellite stable (MSS) tumor confirmed by immunohistochemistry or genetic testing.
  5. No prior anti-tumor treatment.
  6. (ECOG) performance status of 0-1, with an expected survival of at least 3 months.
  7. Adequate organ function, including:

    • ≥1.5 × 10\^9/L
    • count ≥100 × 10\^9/L
    • ≥9 g/dL
    • Serum albumin ≥3 g/dL
    • Total ≤1.5 × (ULN)
    • and AST ≤2 × ULN
    • Serum creatinine ≤1.5 × ULN or ≥60 mL/min
    • or PT ≤1.5 × ULN, and aPTT ≤1.5 × ULN
  8. Thyroid function within normal range or adequately controlled.
  9. Negative pregnancy test for women of .
  10. Willingness to use effective during the study and for 12 months after treatment.
  11. Ability to understand and willingness to sign a written form.
  12. Willingness and ability to comply with study procedures and follow-up.

Exclusion criteria

Exclusion Criteria:

  • Participants will be excluded if they meet any of the following criteria:

    1. Histology other than rectal adenocarcinoma (e.g., gastrointestinal stromal tumor, lymphoma).
    2. Prior pelvic radiotherapy.
    3. Prior treatment with , PD-L1, or CTLA-4 inhibitors.
    4. Known allergy to study drugs or their components.
    5. History of other , except adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, or papillary thyroid carcinoma.
    6. Active disease or history of autoimmune disease requiring systemic treatment.
    7. Immunodeficiency, including infection, or history of organ transplantation.
    8. History of interstitial lung disease or non-infectious pneumonitis.
    9. Active tuberculosis infection or history of untreated tuberculosis.
    10. Active or infection.
    11. Severe cardiovascular, pulmonary, or renal disease.
    12. Uncontrolled hypertension despite medication.
    13. History of substance abuse (alcohol or drugs).
    14. Active uncontrolled infection.
    15. Use of systemic therapy.
    16. Pregnant or breastfeeding women.
    17. Any condition that, in the investigator's opinion, may interfere with study participation or safety.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Serplulimab + H101 + Short-course Radiotherapy + XELOX

    Participants with low rectal adenocarcinoma (cT1-3N0M0) will receive total neoadjuvant therapy consisting of intratumoral oncolytic virus H101, short-course radiotherapy, serplulimab, and XELOX chemotherapy. H101 will be administered on Day 1 of Cycle 1 and Day 1 of Cycle 4. Short-course radiotherapy will be delivered during treatment. Serplulimab and XELOX chemotherapy will be administered every 3 weeks according to the study protocol. Tumor response will be assessed after completion of treatment.

    Drug: Serplulimab · Biological: Oncolytic Virus H101 · Drug: XELOX Chemotherapy · Radiation: Short-course Radiotherapy

Interventions

  • Serplulimab is a humanized monoclonal antibody targeting programmed cell death protein-1 (PD-1). It will be administered intravenously at a fixed dose of 300 mg on Day 1 of each 3-week cycle for a total of 6 cycles. Serplulimab is given in combination with chemotherapy, radiotherapy, and oncolytic virus therapy as part of total neoadjuvant treatment. The aim is to enhance anti-tumor immune response and improve treatment efficacy.

  • BiologicalOncolytic Virus H101

    H101 is a recombinant human adenovirus type 5 oncolytic virus that selectively replicates in and lyses tumor cells while stimulating anti-tumor immune responses. It will be administered by intratumoral injection on Day 1 of Cycle 1 and Day 1 of Cycle 4. The dose will be determined based on tumor size. H101 is used in combination with immunotherapy, chemotherapy, and radiotherapy to enhance tumor cell killing and improve immune activation.

  • DrugXELOX Chemotherapy

    XELOX chemotherapy consists of oxaliplatin and capecitabine. Oxaliplatin will be administered intravenously at a dose of 130 mg/m² on Day 1, and capecitabine will be given orally at a dose of 1000 mg/m² twice daily from Day 1 to Day 14 of each 3-week cycle. A total of 6 cycles will be administered. Chemotherapy is combined with immunotherapy, radiotherapy, and oncolytic virus therapy to improve tumor response.

  • RadiationShort-course Radiotherapy

    Short-course radiotherapy will be delivered to the rectal tumor using intensity-modulated radiation therapy (IMRT). The total dose is 25 Gy administered in 5 fractions over one week. Radiotherapy is given during the treatment course in combination with immunotherapy, chemotherapy, and oncolytic virus therapy. It aims to enhance local tumor control and stimulate anti-tumor immune response.

06

What researchers measure

Primary outcomes

  1. 1-year Clinical Complete Response Rate

    Clinical complete response (cCR) is defined as no evidence of residual tumor based on digital rectal examination, endoscopy showing mucosal healing or scar, and imaging (MRI or CT) without tumor signal or metabolic activity, and no distant metastasis. The proportion of patients achieving cCR and maintaining it for at least 1 year will be evaluated.

    Time frame: 1 year after completion of treatment

Secondary outcomes

  1. Objective Response Rate

    The proportion of participants who achieve complete response (CR) or partial response (PR) based on imaging assessments according to RECIST criteria.

    Time frame: Up to 6 months after treatment initiation

  2. Organ Preservation Rate

    The proportion of patients who achieve clinical complete response and avoid radical surgery, thereby preserving the rectum.

    Time frame: 1 year after completion of treatment

  3. Disease-Free Survival

    Time from treatment initiation to the occurrence of disease recurrence, metastasis, or death from any cause.

    Time frame: Up to 3 years

  4. Overall Survival

    Time from treatment initiation to death from any cause.

    Time frame: Up to 3 years

  5. Incidence of Adverse Events

    The incidence and severity of treatment-related adverse events will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: From treatment initiation up to 3 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to patient privacy concerns and institutional data protection policies. De-identified data may be available upon reasonable request to the corresponding investigator, subject to approval.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Dec 2028, 31 months later.

Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 31 months is below that.

Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 22, 2026
StartEst.
May 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07543848
Lead sponsor
Chongqing University Cancer Hospital
Responsible party
Bo Yi (Chief Physician, Chongqing University Cancer Hospital) — Principal investigator
First posted
Apr 22, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 22, 2026

Study contacts

Bo Yi, MD
Contact
yibo2018pro@126.com
+86-137-8617-9533

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serplulimab

Start the discussion